Prevalence and Predictors of Metabolic Syndrome Among Patients Attending an Outpatient Clozapine Clinic in Australia

Archives of Psychiatric Nursing

Volumn 23, Issue 3, 2009, Pages 261-268

  Brunero, Scott ^a   Lamont, Scott ^a   Fairbrother, Greg ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; AUSTRALIA; BLOOD; COMORBIDITY; CROSS-SECTIONAL STUDY; DRUG MONITORING; FEMALE; HEALTH SERVICE; HEALTH SURVEY; HUMAN; MALE; MASS SCREENING; METABOLIC SYNDROME X; MULTIVARIATE ANALYSIS; OUTPATIENT; OUTPATIENT DEPARTMENT; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; STATISTICAL MODEL; STATISTICS;

ADULT; AMBULATORY CARE FACILITIES; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COMORBIDITY; CROSS-SECTIONAL STUDIES; DRUG MONITORING; FEMALE; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; LOGISTIC MODELS; MALE; MASS SCREENING; METABOLIC SYNDROME X; MULTIVARIATE ANALYSIS; NEW SOUTH WALES; OUTPATIENTS; POPULATION SURVEILLANCE; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SCHIZOPHRENIA;

EID: 65549095381     PISSN: 08839417     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apnu.2008.06.007     Document Type: Article

References (50)

1. Alphs L., and Anand R. Clozapine: The commitment to patient safety. Journal of Clinical Psychiatry 60 (1999) 39-42
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (1994) Washington, DC
3. Babidge N., Buhrich N., and Butler T. Mortality among homeless people with schizophrenia in Sydney, Australia: A 10 year follow up. Acta Psychiatrica Scandanivica 103 (2001) 81
4. Berk M., Fitzsimmons J., Lambert T., Pantelis C., Kurkani J., Castle D., et al. Monitoring the safe use of clozapine. CNS Drugs 21 (2007) 117-127
5. Brunero S., Lamont S., Myrtle L., and Fairbrother G. Blue Card: A hand-held health record card for mental health consumers with co-morbid physical health risk. Australasian Psychiatry 7 16 (2008) 238-243
6. Correll C., Frederickson A., Kane J., and Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophrenia Research 89 (2007) 91-100
7. Colton C., and Manderscheid R. Congruencies in increased mortality rates years of potential life lost, and causes of death among public mental health clients in eight states. Preventing Chronic Disease 3 (2006) 1-13
8. Dixon L., Weiden P., Delahanty J., Goldberg R., Postrado L., Lucksted A., et al. Prevalence and correlates of diabetes in national schizophrenic samples. Schizophrenia Bulletin 26 (2000) 903-912
9. Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain. Drug Safety 29 (2006) 303-319
10. Goethe J., Szarek B., Caley C., and Woolley S. Signs and symptoms associated with the metabolic syndrome in psychiatric inpatients receiving antipsychotics. A retrospective chart review. Journal of Clinical Psychiatry 68 (2007) 22-28
11. Henderson D., Cageliero E., Gray C., Nasrallah R., Hayden D., Schoenfeld D., et al. Clozapine, diabetes mellitus, weigh gain, and lipid abnormalities: A five year naturalistic study. American Journal of Psychiatry 157 (2000) 975-981
12. Henderson D., Louie P., Koul P., Namey L., Daley T., and Nguyen D. Modafinil-associated weight loss in a clozapine-treated schizoaffective disorder patient. Annals of Clinical Psychiatry 17 (2005) 95-97
13. Holmberg S., and Kane C. Health and self-care practices of persons with schizophrenia. Psychiatric Services 50 (1999) 827-829
14. Holt R. Association between antipsychotic drugs and diabetes. Diabetes, Obesity and Metabolism 8 (2006) 125-135
15. International Diabetes Federation. Worldwide definition of the metabolic syndrome. Available at: (2007). http://www.idf.org/home/index.cfm?unode=1120071E-AACE-41D2-9FA0-BAB6E25BA072 Accessed 14th February 2008
16. Kane J., Honigfeld G., Singer J., and Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double blind comparison with chlorpromazine. Archives of General Psychiatry 45 (1988) 789-796
17. Kohen D. Physical health in mental illness: Psychiatric shared responsibility. Advances in Psychiatric Treatment 11 (2005) 457-458
18. L'Italien G., Casey D., Kan H., Carson W., and Marcus R. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripriprazole versus olanzapine or placebo. Journal of Clinical Psychiatry 68 (2007) 1510-1516
19. Lambert T., Velakoulis D., and Pantelis C. Medical co morbidity in schizophrenia. Medical Journal of Australia 178 (2003) s67-s70
20. Lamberti J., Olson D., Crilly J., Olivares T., Williams G., Tu X., et al. Prevalence of the metabolic syndrome among patients receiving clozapine. American Journal of Psychiatry 163 (2006) 1273-1275
21. Lawrence D., Holman D., Jablensky A., and Hobbs M. Death rate from ischaemic heart disease in Western Australian psychiatric patients 1980-1998. British Journal of Psychiatry 182 (2003) 31-36
22. Lewis S., Barnes T., Davies L., Murray R., Dunn G., Hayhurst K., et al. Randomised controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bulletin 32 (2006) 715-723
23. Mackin P., Watkinson H., and Young A. Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: A cross-sectional study. Diabetlogia 48 (2005) 215-221
24. McCabe R., Saidi M., and Priebe S. Patient-reported outcomes in schizophrenia. British Journal of Psychiatry 191 (2007) s21-s28
25. Mcevoy J., Meyer J., Goff D., Nasrallah H., Davis S., Sullivan L., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research 80 (2005) 19-32
26. Mclaughlin T., Reaven G., Abbasi F., Lamendola C., Saad M., Waters D., et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?. American Journal of Cardiology (2005). www.AJConline.org
27. Miles C. Conditions predisposing to suicide: A review. Journal of Nervous and Mental Disorders 164 (1977) 231-245
28. National Suicide Prevention Strategy. Department of Health and Ageing (1999). http://www.aodgp.gov.au/internet/wcms/publishing.nsf/Content/mental-suicide-overview Accessed 15th February 2008
29. National Cholesterol Education Program. National Cholesterol Education Program (NCEP) (1985). http://www.nhlbi.nih.gov/about/ncep/ Accessed 17th June 2008
30. Nasrallah H. Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectrums 11 (2006) 32-39
31. Newcomer J. Antipsychotic medications: Metabolic and cardiovascular risk. Journal of Clinical Psychiatry 68 (2007) 8-13
32. Newcomer J. Metabolic considerations in the use of antipsychotic medication: A review of recent evidence. Journal of Clinical Psychiatry 68 (2007) 20-27
33. Palmer B., Pankratz S., and Bostwick J. The lifetime risk of suicide in schizophrenia. Archives of General Psychiatry 62 (2005) 247-253
34. Procyshyn R., Wasan K., Thornton A., Barr A., Chen E., Pomarol-Clotet E., et al. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long term clozapine treatment. Journal of Psychiatry Neuroscience 32 (2007) 331-338
35. Rationale for the New Worldwide Definition of Metabolic Syndrome. Available at: (2007). http://www.idf.org/webdata/docs/Metabolic_syndrome_rationale.pdf Accessed 14th February 2008
36. Ruano G., Zollner S., and Goeth J. Drug-induced metabolic syndrome (DMS) in psychiatry: A diagnostic need uniquely suited to pharmacogenomics. In: Linder M., Valdes Jr. R., and Wong S. (Eds). Clinical pharmacogenomics (2005), AACC Press, American Association of Clinical Chemistry
37. Ruschena D., Mullen P., Burgess P., Cordner S., Barry-Walsh J., Drummer O., et al. Sudden death in psychiatric patients. British Journal of Psychiatry 173 (1998) 270-271
38. Ryan M., Collins P., and Thakore J. Impaired fasting glucose tolerance in first episode, drug naive patients with schizophrenia. American Journal of Psychiatry 160 (2003) 284-289
39. Saha S., Chant D., and Mcgrath J. A systematic review of mortality in schizophrenia. Archives of General Psychiatry 64 (2007) 1123-1131
40. Sernyak M. Implementation of monitoring and management guidelines for second generation antipsychotics. Journal of Clinical Psychiatry 68 (2007) 14-18
41. Straker D., Correll C., Kramer-Ginsberg E., Abdulhamid N., Koshy F., Rubens E., et al. Cost effective screening for the metabolic syndrome in patients treated with second generation antipsychotic medications. American Journal of Psychiatry 162 (2005) 1217-1221
42. Suvisaari J., Saarni S., Perala J., Suvisaari J., Harkanen T., Lonnqvist J., et al. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. Journal of Clinical Psychiatry 68 (2007) 1045-1055
43. Thakore J. Metabolic disturbance in first-episode schizophrenia. British Journal of Psychiatry 184 (2004) s76-s79
44. Thomas P. The stable patient with schizophrenia-from antipsychotic effectiveness to adherence. European Neuropsychopharmacology 17 (2007) s115-s122
45. Usher K., Foster K., and Park T. The metabolic syndrome and schizophrenia: The latest evidence and nursing guidelines for management. Journal of Psychiatric and Mental Health Nursing 13 (2006) 730-734
46. Volvaka J., Nolan K., Kline L., Czobor P., Citrome L., Sheitman B., et al. Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation. Schizophrenia Research 76 (2005) 127-129
47. World Health Organization. In: Alwan A., and King H. (Eds). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus (1999), World Health Organization, Department of Non communicable Disease Surveillance, Geneva 1-59
48. Wirshing D., Wirshing W., Nystrom M., and Buc P. Medicolegal considerations in the treatment of psychosis with second generation antipsychotics. Psychiatric Times 21 (2004)
49. Wu M., Wang C., Bai Y., Huang C., and Lee S. Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six month diet and physical activity program. Psychiatric Services 58 (2007) 544-550
50. Yumru M., Savas H., Kurt E., Kaya M., Selek S., Savas E., et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. Journal of Affective Disorders 98 (2007) 247-252